Abstract:Autosomal recessive Charcot-Marie-Tooth disease Type 2S (AR-CMT2S) caused by IGHMBP2 mutation was first reported in 2014, and an increasing number of cases have been reported in the past eight years. We detected 15 distinct IGHMBP2 mutations among 8 typical AR-CMT2S families in our cohort of 178 Chinese CMT2 families using Sanger sequencing and next-generation sequencing (NGS), making IGHMBP2 mutations the most frequent cause of AR-CMT2 in our cohort. From 2014 to 2022, 34 AR-CMT2S families, including 45 patients and 47 different mutations, were reported. One third of identified mutations represented presumed loss-of-function variants (nonsense, frameshift and splicing), while two-thirds were missense changes which clustered in the helicase and ATPase domains. The age at onset ranged from 0.11 years to 20 years (mean±SD: 3.76±3.93 years) and the infantile (0–2 years) onset group accounted for the most patients (51.1%). The initial symptoms included muscle weakness (15, 33.3%), delayed milestones (9, 20%), feet deformity (8, 17.8%), gait disturbance (8, 17.8%), feet drop (7, 15.6%), frequent falls (3, 6.7%), hypotonia (2, 4.4%) and thenar atrophy (1, 2.2%). Molecular structural model analysis of 26 missense IGHMBP2 mutations using PyMOL software revealed that six mutations were close to the RNA-binding channel, eight mutations were in or close to the nucleotide-binding pocket. Based on available limited clinical information, it seems possible that missense changes located in or close to these motifs might be linked to a more severe clinical outcome. In conclusion, IGHMBP2 mutation screening should recommended for early-onset, moderately or severely affected, and sporadic or AR-CMT2 patients. A tiny minority of patients were relatively late onset and mild affected, which should be given more attention in genetic diagnosis and treatment. While our preliminary analysis suggests a potential link between the localization of missense mutations and clinical presentation, definition of genotype-phenotype relationships will require harmonized clinical information from a larger series of patients.

Models for IGHMBP2-associated diseases: an overview and a roadmap for the future

The molecular mechanisms that underlie IGHMBP2-related diseases.

Disease Mechanisms and Therapeutic Approaches in SMARD1—Insights from Animal Models and Cell Models

The contribution and therapeutic implications of IGHMBP2 mutations on IGHMBP2 biochemical activity and ABT1 association

Exploring the relationship between IGHMBP2 gene mutations and spinal muscular atrophy with respiratory distress type 1 and Charcot-Marie-Tooth disease type 2S: a systematic review

The Ighmbp2 Helicase Structure Reveals the Molecular Basis for Disease-Causing Mutations in DMSA1

In Vitro Modeling as a Tool for Testing Therapeutics for Spinal Muscular Atrophy and IGHMBP2-Related Disorders

Clinically relevant mouse models of Charcot-Marie-Tooth Type 2S.

Defective Membrane Remodeling in Neuromuscular Diseases: Insights from Animal Models

Charcot–Marie‐Tooth type 2A in vivo models: Current updates

Molecular Mechanisms and Animal Models of Spinal Muscular Atrophy.

The systemic complexity of a monogenic disease: the molecular network of spinal muscular atrophy

Clinical and genetic features of Charcot-Marie-Tooth disease patients with IGHMBP2 mutations

Understanding Genetic Pathways, Disease Models, and Potential Therapeutic Approaches

IGHMBP2 -Related Clinical and Genetic Features in a Cohort of Chinese Charcot–Marie–Tooth Disease Type 2 Patients

A perspective on human cell models for POLG-spectrum disorders: advantages and disadvantages of CRISPR-Cas-based vs. patient-derived iPSC models

Clinical and molecular features and therapeutic perspectives of spinal muscular atrophy with respiratory distress type 1

Spinal Muscular Atrophy Modeling and Treatment Advances by Induced Pluripotent Stem Cells Studies

Axonal defects in mouse models of motoneuron disease

Clinical diversity caused by novel IGHMBP2 variants

The use of genetically humanized animal models for personalized medicine approaches